CI Global Healthcare Leaders Index ETF

CBOE CANADA TICKER : CHCL.B
As of April 4, 2025 CI Bio-Revolution Index ETF COMMON UNITS (CDNA) merged into (CHCL.B)
 

Fund overview

CHCL seeks to replicate, to the extent reasonably possible, the performance of a global healthcare index, net of expenses. Currently, CHCL seeks to replicate the performance of the Solactive Developed Markets Healthcare 150 CAD Index (CA NTR). The Index intends to track the performance of the largest 150 companies from the global healthcareindustry.

Fund details

description of elementelement value
Inception date August 2021
Total net assets ($CAD)
As at 2025-07-04
$135.2 million
NAVPS
As at 2025-07-04
$21.3612
Market price
As at 2025-02-28
$24.0400
MER (%)
As at 2024-12-31
0.37
Management fee (%) 0.35
Units outstanding
As at 2025-07-04
6,331,800
Asset class Sector Equity
Currency CAD
CUSIP 12567E109
Distribution frequency Quarterly
Last distribution $0.1261

Risk rating1

  • Low
  • Low to medium
  • Medium
  • Medium to high
  • High

Investor suitability

For those who:
  • want exposure to the largest 150 companies from the global healthcare industry
  • are investing for the medium and/or long term
  • can tolerate medium risk

Performance2 As at 2025-06-30

Growth of $10,000 (Since inception date)

growth of 10k graph

Calendar year performance

annual performance graph

average annual compound returns

YTD 1 Mo 3 Mo 6 Mo 1 Y 3 Y 5 Y 10 Y Inception*
-4.77% 0.63% -9.10% -4.77% -6.28% 5.45% - - 3.02%
*Since inception date

Distribution history3

Ex-Date Total
2025-06-24 0.1261
2025-03-25 0.0478
2024-12-23 0.0600
2024-09-23 0.0495
2024-06-24 0.1157
Ex-Date Total
2024-03-21 0.0281
2023-12-20 0.1000
2023-09-22 0.0541
2023-06-23 0.0587
2023-03-24 0.0283

Management team

First we'll display the Team Company and then the Team members
CI Global Asset Management ETF

CI Global Healthcare Leaders Index ETF

CBOE CANADA TICKER : CHCL.B
As of April 4, 2025 CI Bio-Revolution Index ETF COMMON UNITS (CDNA) merged into (CHCL.B)
 
Portfolio allocations4 As at 2025-05-31
Asset allocation (%)
  • US Equity 68.76
  • International Equity 31.23
  • Cash and Equivalents 0.01
Sector allocation (%)
  • Healthcare 95.89
  • Consumer Services 1.99
  • Consumer Goods 1.70
  • Industrial Goods 0.41
  • Cash and Cash Equivalent 0.01
Geographic allocation(%)
  • United States 68.76
  • Switzerland 8.65
  • United Kingdom 5.10
  • Japan 4.38
  • Denmark 3.52
  • France 2.76
  • Other 1.95
  • Ireland 1.92
  • Germany 1.50
  • Australia 1.46
Top holdings5
Sector (%)
1. Eli Lilly and Co Drugs 8.74%
2. Johnson & Johnson Drugs 5.23%
3. AbbVie Inc Drugs 4.60%
4. UnitedHealth Group Inc Healthcare Services 3.85%
5. Abbott Laboratories Healthcare Equipment 3.22%
6. Roche Holding AG - Partcptn Drugs 3.18%
7. Novartis AG Cl N Drugs 3.16%
8. Novo Nordisk A/S Cl B Drugs 3.05%
9. AstraZeneca PLC Drugs 3.04%
10. Intuitive Surgical Inc Healthcare Equipment 2.75%
11. Merck & Co Inc Drugs 2.71%
12. Boston Scientific Corp Healthcare Equipment 2.17%
13. Amgen Inc Drugs 2.16%
14. Thermo Fisher Scientific Inc Healthcare Equipment 2.12%
15. Gilead Sciences Inc Drugs 1.91%
Over 35,000 financial advisors have chosen CI Global Asset Management as a partner. We believe that Canadians have the best opportunity for investments success by using the services of a professional financial advisor. Learn more at ci.com.